CLINICAL TRIALS PROFILE FOR PIPERACILLIN AND TAZOBACTAM

All Clinical Trials for PIPERACILLIN AND TAZOBACTAM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003805 ↗	Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1997-11-01	RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.
NCT00044746 ↗	Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 4	2000-10-01	Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.
NCT00044759 ↗	Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	1969-12-31	To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
NCT00167999 ↗	Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units	Completed	Wyeth is now a wholly owned subsidiary of Pfizer		2005-02-01	To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
NCT00195286 ↗	Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.	Completed	Wyeth is now a wholly owned subsidiary of Pfizer		2004-06-01	The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections
NCT00195533 ↗	Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients	Completed	PETHEMA (Program for the Study and Treatment of Haematological Malignances)		2001-07-01	The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for fever in neutropenic patients. Study of consecutive cohorts(2). First the patients will be included in the monotherapy branch until completing the predicted number of cases. When this happens, the Coordinating Center will communicate it to the participant centers and from then the patients will be included in the combined therapy.
NCT00195533 ↗	Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients	Completed	Wyeth is now a wholly owned subsidiary of Pfizer		2001-07-01	The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for fever in neutropenic patients. Study of consecutive cohorts(2). First the patients will be included in the monotherapy branch until completing the predicted number of cases. When this happens, the Coordinating Center will communicate it to the participant centers and from then the patients will be included in the combined therapy.

Clinical Trial Conditions for PIPERACILLIN AND TAZOBACTAM

Condition Name

Condition Name for PIPERACILLIN AND TAZOBACTAM
Intervention	Trials
Sepsis	5
Septic Shock	5
Bacteremia	4
Pneumonia	4

Condition MeSH

Condition MeSH for PIPERACILLIN AND TAZOBACTAM
Intervention	Trials
Infections	25
Infection	23
Communicable Diseases	17
Sepsis	10

Clinical Trial Locations for PIPERACILLIN AND TAZOBACTAM

Trials by Country

Trials by Country for PIPERACILLIN AND TAZOBACTAM
Location	Trials
United States	121
China	23
Italy	16
France	15
Germany	15

Trials by US State

Trials by US State for PIPERACILLIN AND TAZOBACTAM
Location	Trials
Florida	8
Texas	8
California	7
Missouri	6
Illinois	5

Clinical Trial Progress for PIPERACILLIN AND TAZOBACTAM

Clinical Trial Phase

Clinical Trial Phase for PIPERACILLIN AND TAZOBACTAM
Clinical Trial Phase	Trials
Phase 4	29
Phase 3	24
Phase 2/Phase 3	6

Clinical Trial Status

Clinical Trial Status for PIPERACILLIN AND TAZOBACTAM
Clinical Trial Phase	Trials
Completed	43
Not yet recruiting	12
Unknown status	11

Clinical Trial Sponsors for PIPERACILLIN AND TAZOBACTAM

Sponsor Name

Sponsor Name for PIPERACILLIN AND TAZOBACTAM
Sponsor	Trials
Merck Sharp & Dohme Corp.	9
Wyeth is now a wholly owned subsidiary of Pfizer	8
M.D. Anderson Cancer Center	5

Sponsor Type

Sponsor Type for PIPERACILLIN AND TAZOBACTAM
Sponsor	Trials
Other	157
Industry	43
U.S. Fed	2